Fanastomig Biosimilar – Anti-FDC; CD279 mAb – Research Grade from ProteoGenix; catalogue PX-TA2118; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Fanastomig Biosimilar, also known as Anti-FDC, CD279 mAb, is a novel monoclonal antibody (mAb) that has been developed as a potential therapeutic agent for various diseases. This biosimilar is a highly specific and potent antibody that targets the follicular dendritic cells (FDCs) and CD279, also known as programmed cell death protein 1 (PD-1). In this article, we will discuss the structure, activity, and potential applications of Fanastomig Biosimilar as a research-grade antibody.
Fanastomig Biosimilar is a recombinant humanized IgG1 monoclonal antibody that has been developed using advanced genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Fanastomig Biosimilar is specifically designed to bind to FDCs and CD279, while the constant region is responsible for effector functions such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC).
The amino acid sequence of Fanastomig Biosimilar has been carefully engineered to ensure high specificity and minimal immunogenicity. It has a molecular weight of approximately 150 kDa and a half-life of around 21 days, making it a stable and long-lasting antibody.
Fanastomig Biosimilar exerts its therapeutic effects by binding to FDCs and CD279 on the surface of immune cells. FDCs are specialized cells found in lymphoid tissues that play a critical role in the activation and regulation of the immune response. CD279, on the other hand, is a co-inhibitory receptor that is expressed on activated T cells and plays a key role in immune tolerance.
By targeting FDCs, Fanastomig Biosimilar can disrupt the formation of germinal centers, which are essential for the development of B cell-mediated immune responses. This can be beneficial in diseases where abnormal B cell activation and proliferation contribute to disease progression, such as autoimmune disorders and certain types of cancer.
Furthermore, by binding to CD279, Fanastomig Biosimilar can block the inhibitory signal that is normally transmitted to T cells, thereby enhancing their activity and promoting an anti-tumor immune response. This mechanism of action makes Fanastomig Biosimilar a promising therapeutic agent for cancer immunotherapy.
Fanastomig Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various diseases. Some potential applications of this biosimilar include:
Fanastomig Biosimilar is a novel monoclonal antibody that targets FDCs and CD279, making it a promising therapeutic agent for various diseases. Its unique mechanism
ProteoGenix catalogue number PX-TA2118. For research use only.
Target: Fanastomig Biosimilar – Anti-FDC; CD279 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Fanastomig Biosimilar – Anti-FDC; CD279 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
